Clinical Trial Update: Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-conducted Phase 1/2 trial in immunocompromised children (ages 2-17) assessed safety, tolerance, and pharmacokinetics of the antifungal anidulafungin in n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• Eraxis (anidulafungin)

Snippet

Sponsor: Pfizer | Conditions: Neutropenia | Phase 1, Phase 2 | Status: COMPLETED